Skip to main content

Table 3 Treatment-related adverse events

From: Safety and efficacy of sirolimus in recurrent intravenous leiomyomatosis, pulmonary benign metastatic leiomyomatosis, and leiomyomatosis peritonealis disseminata: a pilot study

Adverse events

Any grade

No.(%)

Grade 1/2

No.(%)

Grade 3/4

No.(%)

Any

9 (60.0)

7

2

Mouth ulcer

5 (33.3)

4

1

Elevated liver enzymes

2 (13.3)

2

0

Dyslipidemia

1 (6.67)

1

0

Maculopapule

1 (6.67)

0

1